NCT01599754
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01599754
Title Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
Acronym ATLAS
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors SFJ Pharmaceuticals, Inc.
Indications
Therapies
Age Groups: adult
Covered Countries USA | FRA | ESP

Facility Status City State Zip Country Details
La Jolla California 92093 United States Details
Los Angeles California 90033 United States Details
Palo Alto California 94304 United States Details
Pleasant Hill California 94523 United States Details
Denver Colorado 80218 United States Details
Washington D.C. District of Columbia 20007 United States Details
Ocala Florida 34471 United States Details
Atlanta Georgia 30322 United States Details
Annapolis Maryland 21403 United States Details
Baltimore Maryland 21231-1000 United States Details
Saint Paul Minnesota 55118 United States Details
Omaha Nebraska 68198 United States Details
Hackensack New Jersey 07601 United States Details
Albany New York 12208 United States Details
New York New York 10467 United States Details
Portland Oregon 97227 United States Details
Charleston South Carolina 29412 United States Details
Chattanooga Tennessee 37421 United States Details
Austin Texas 78731 United States Details
Bedford Texas 76022 United States Details
Dallas Texas 75203 United States Details
Houston Texas 77024 United States Details
San Antonio Texas 78217 United States Details
San Antonio Texas 78234 United States Details
Norfolk Virginia 23502 United States Details
Seattle Washington 95109 United States Details
Beijing China Details
Changchun China Details
Chongqing China Details
Dalian China Details
Guangzhou China Details
Hangzhou China Details
Jinan China Details
Nanchang China Details
Shanghai China Details
Suzhou China Details
Tianjin China Details
Wuhan China Details
Besançon France Details
Bordeaux France Details
Hyères France Details
Le Mans France Details
Lyon France Details
Marseille France Details
Paris France Details
Rennes France Details
Saint-Herblain France Details
Suresnes France Details
Vandœuvre-lès-Nancy France Details
Hong Kong Hong Kong Details
Ahmeadbad India Details
Aurangabad India Details
Bangalore India Details
Chennai India Details
Hyderabad India Details
Karamsad India Details
Kochi India Details
Kolkota India Details
Lucknow India Details
Ludhiana India Details
Mangalore India Details
Manipal India Details
Mumbai India Details
Nashik India Details
New Delhi India Details
Pune India Details
Surat India Details
Visakhapatnam India Details
Aichi Japan Details
Akita Japan Details
Aomori Japan Details
Chiba Japan Details
Fukuoka Japan Details
Gifu Japan Details
Hokkaido Japan Details
Hyōgo Japan Details
Kagawa Japan Details
Kanagawa Japan Details
Kumamoto Japan Details
Kyoto Japan Details
Nagasaki Japan Details
Nigata-honmachi Japan Details
Osaka Japan Details
Shizuoka Japan Details
Tokushima Japan Details
Tokyo Japan Details
Yamagata Japan Details
Yamaguchi Japan Details
Busan South Korea Details
Daegu South Korea Details
Daejeon South Korea Details
Gyeonggi-do South Korea Details
Jeonnam South Korea Details
Seoul South Korea Details
Barcelona Spain Details
Donostia / San Sebastian Spain Details
Leganés Spain Details
Llobregat Spain Details
Madrid Spain Details
Oviedo Spain Details
Seville Spain Details
Valencia Spain Details
Zaragoza Spain Details
Taichung Taiwan Details
Taipei Taiwan Details
Taoyuan District Taiwan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field